Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebecototumab + bevacizumab with re-radiotherapy in recurrent high-grade glioma
ChiCTR2600130332Phase 2Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vebecototumab and bevacizumab in glioma, sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Objective Response Rate. Started Aug 2026; status: recruiting.
02
Drugs
vebecototumabbevacizumab
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2600130332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130332.